Clinical Trial Update: Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial is planned to compare surufatinib plus gemcitabine and nab-paclitaxel against gemcitabine and nab-paclitaxel as neoadjuvant therapy for high-ris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Pancreatic Cancer, Adult | Phase 3 | Status: NOT_YET_RECRUITING